UK's NICE recommends use of Cimzia (certolizumab pegol) in active psoriatic arthritis- UCB
The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol), from UCB, alone, or in combination with methotrexate, for adults with active psoriatic arthritis if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks, and the drug is provided under the conditions of a patient access scheme.
Use should also follow existing NICE guidance psoriatic arthritis treatment with etanercept (Pfizer's Enbrel), infliximab (MSD's Remicade, Napp Pharmaceuticals' Remsima, and Hospira's Inflectra) and adalimumab (AbbVie's Humira), the Institute noted.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma